🤖 Generated with AI assistance · Does not replace individualized medical advice.
AI Act Transparency Notice
This content was generated with the assistance of artificial intelligence tools. It is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified health provider with any questions regarding a medical condition.
Comparative Evaluation of LLMs in Lung Cancer: Context-Dependent Performance in a Double-Blind Study
Lead
A double-blind study evaluated ChatGPT, DeepSeek, and Grok across nine simulated lung cancer cases. No single model consistently outperformed others; performance was context-dependent, with Grok leading in diagnosis and DeepSeek in prognosis.
Key Facts
| Metric | Value |
|---|---|
| Models Evaluated | 3 (ChatGPT, DeepSeek, Grok) |
| Clinical Cases | 9 simulated lung cancer scenarios |
| Inter-rater Agreement | Moderate (Fleiss’ κ = 0.463) PMID: 42719007 |
| Statistical Significance | No significant differences (P > 0.05) PMID: 42719007 |
Why It Matters / Context
Lung cancer remains the leading cause of cancer-related mortality worldwide, necessitating precise clinical decision support PMID: 42719007. While Large Language Models (LLMs) have shown promise in this domain, previous evaluations often relied on aggregate metrics or isolated tasks, failing to capture the complexity of real-world clinical workflows PMID: 42719007.
This study addresses that gap by employing a task-specific evaluation framework. By anonymizing and randomizing LLM outputs, the researchers ensured that senior specialists could score responses without bias toward a specific vendor. The finding that no single LLM dominates across all domains suggests that “best model” rankings are insufficient for clinical integration. Instead, the choice of AI tool may need to be tailored to specific clinical tasks, such as diagnostic reasoning versus prognostic counseling. This shift from general benchmarking to task-specific validation is critical for the safe deployment of AI in oncology.
Details
The study utilized a rigorous double-blind design where five senior lung cancer specialists independently scored the outputs of three LLMs: ChatGPT, DeepSeek, and Grok. The evaluation covered nine simulated lung cancer cases spanning five clinical domains. The scoring mechanism employed a five-point Likert scale assessing four dimensions: accuracy, comprehensiveness, relevance, and clinical applicability.
Methodological Rigor:
- Blinding: Outputs were anonymized and randomized to prevent model identification bias.
- Scoring: Five senior specialists provided independent scores.
- Agreement: Inter-rater agreement was moderate, with a Fleiss’ κ of 0.463 and an Intraclass Correlation Coefficient (ICC) of 0.675 PMID: 42719007.
Performance Patterns:
While all LLMs achieved high scores across evaluation dimensions without statistically significant differences (P > 0.05), descriptive analyses revealed distinct context-dependent patterns PMID: 42719007.
| Model | Observed Performance Pattern |
|---|---|
| Grok | Tended to show more consistent performance in diagnosis and treatment decision-making PMID: 42719007. |
| DeepSeek | Showed comparatively lower descriptive performance in therapeutic decisions but higher applicability in prognosis and rehabilitation PMID: 42719007. |
| ChatGPT (GPT) | Exhibited relatively stable intermediate performance across domains PMID: 42719007. |
The qualitative error analysis further supported the notion that performance is not uniform. For instance, a model excelling in diagnostic accuracy might lag in the nuanced language required for rehabilitation planning. This heterogeneity implies that a “one-size-fits-all” approach to AI integration in oncology is likely suboptimal.
Limitations
Critical Limitation: The study is explicitly exploratory and relies on a limited number of simulated cases (n=9). The authors caution that these findings should be interpreted with care due to the small sample size, which limits the generalizability of the results to broader clinical populations PMID: 42719007. Additionally, the moderate inter-rater agreement (κ = 0.463) suggests that subjective scoring of complex clinical narratives remains challenging, potentially introducing variability in the assessment of “clinical applicability.”
Clinical Takeaway
Clinicians and health systems should avoid adopting a single LLM for all oncology tasks; instead, they should pilot specific models for specific workflows (e.g., diagnostic support vs. patient communication) based on task-specific performance data.
Full Reference
Zhang W, Li X, Yuan R, Zhang Y, Yang Y, Xu Y. Exploratory task-specific evaluation of large language models in lung cancer clinical scenarios: A comparative study. Digital Health. 2026. PMID: 42719007 [DOI: 10.1177/20552076261487079]